Simcere Pharma (SCR) Announces Agreement to Acquire Tianjin Tianda Pharma; To Manufacture Rosuvastatin
More News related to SCR
- Simcere Pharma (SCR) Posts Q3 EPS of 4c, Misses Views
- Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results
- Trading Radar for 11/16: Lowe's (LOW), Pacific Sunwear (PSUN), Assured Guaranty (AGO), Franklin Covey (FC) Report
- Simcere Pharma (SCR) Announces Agreement to Acquire Tianjin Tianda Pharma; To Manufacture Rosuvastatin
- Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
Simcere Pharmaceutical Group (NYSE: SCR) today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda. Rosuvastatin was first marketed by Astrazeneca as Crestor in 2003 and is an effective statin to treat high cholesterol and related conditions.
Upon completion of the acquisition, Simcere will start manufacturing Rosuvastatin.
Related Categories
Corporate NewsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
